GlassScriptPhysician profile
Daphne M Bilbrew
NPI 1194809822
$5,687.13
in general payments reported to CMS, 2019-2025
31 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $429 · 2021: $841 · 2022: $994 · 2023: $677 · 2024: $973 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,485 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.90 |
| Education | $168.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $708.04 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $511.45 | 2019-2024 | Auryxia, Vafseo |
| Otsuka America Pharmaceutical, INC. | $486.41 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $472.66 | 2021-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $390.27 | 2019-2024 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $355.49 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $344.30 | 2019-2025 | Velphoro |
| Aurinia Pharma U.S., INC. | $307.45 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $271.30 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $230.62 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $223.00 | 2024-2025 | |
| Amgen INC. | $193.18 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Glaxosmithkline, LLC. | $142.27 | 2020-2025 | Benlysta, Arexvy, Shingrix |
| Ardelyx, INC. | $136.92 | 2023-2025 | Ibsrela |
| Nxstage Medical, INC. | $127.62 | 2025 | Nxstage System One, Nxstage Pureflow Solution, Nxstage Cartridge Express |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $126.75 | 2021-2023 | Hetlioz, Fanapt |
| Ani Pharmaceuticals, INC. | $117.37 | 2022-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $84.48 | 2023-2025 | Filspari |
| Mallinckrodt Enterprises LLC | $73.60 | 2019 | |
| Lilly USA, LLC | $68.54 | 2023-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.02 | 2021-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $45.86 | 2019-2021 | |
| Daiichi Sankyo INC. | $40.88 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.55 | 2019-2025 | Voyxact |
| Takeda Pharmaceuticals U.S.A., INC. | $29.60 | 2024 | Livtencity |
| Scpharmaceuticals INC. | $27.77 | 2024 | |
| Novo Nordisk INC | $19.99 | 2025 | Ozempic |
| Apellis Pharmaceuticals, INC. | $16.49 | 2025 | Empaveli |
| Baxter Healthcare | $16.33 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.59 | 2025 | Tryvio |
| Genentech USA, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphne Bilbrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.